Pembrolizumab-Induced Cold Agglutinin Disease

被引:3
|
作者
Atiq, Osman [1 ]
Atiq, Saad O. [2 ]
Atiq, Zainab O. [3 ]
Patel, Vijay [4 ]
Atiq, Mohammad O. [5 ]
Atiq, Omar T. [6 ]
机构
[1] Unity Hlth, Dept Internal Med, Searcy, AR 72143 USA
[2] Duke Univ, Dept Internal Med, Durham, NC USA
[3] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA
[4] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[5] Baylor Univ, Dept Hematol & Oncol, Houston, TX 77030 USA
[6] Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA
来源
关键词
Anemia; Hemolytic; Autoimmune; Immunotherapy; Lung Neoplasms; AUTOIMMUNE HEMOLYTIC-ANEMIA;
D O I
10.12659/AJCR.924283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patient: Female, 58-year-old Final Diagnosis: Cold agglutinin disease . lung adenocarcinoma Symptoms: Anemia . fatigue . GI bleeding . neck mass . thrombocytopenia Medication: - Clinical Procedure: - Specialty: Hematology . General and Internal Medicine . Oncology Objective: Unusual clinical course Background: The introduction of immunotherapy in the management of metastatic lung cancer appears to be changing their natural history. Most patients tolerate immunotherapy without any significant adverse events. Nevertheless, a significant number of patients still experience adverse effects. Autoimmune hemolytic anemia has been described as mostly related to warm autoantibodies. The following case report describes cold agglutinin disease with hemolysis secondary to Pembrolizumab therapy for the treatment of metastatic lung cancer. Case Report: A 58-year-old woman noted a left neck mass 4 months prior to her presentation. A biopsy confirmed the presence of metastatic adenocarcinoma, consistent with primary lung cancer. Further evaluation revealed the tumor to be PDL-1-positive. She was started on Pembrolizumab, Pemetrexed, and carboplatin chemotherapy regimen. Her CBC was within normal limits when she started therapy, but within 4 weeks hemoglobin dropped to 4.3 g/dL. Further evaluation showed high cryoglobulin levels and a high cold agglutinin titer. Complement C3 DAT was positive. A peripheral smear showed clumps of red cells and the serum IgM was elevated. The diagnosis of CAD was made. She was then started on Rituximab. Imaging showed a significant response, with decreased disease burden. Conclusions: Our case shows a unique presentation of CAD, initially presumed to be myelosuppression secondary to chemotherapy. Instead, a peripheral smear revealed Pembrolizumab to be the cause of cold agglutinin disease. Due to the relatively unknown association between these 2 entities, patient care was delayed. Finally, after initiation of Rituximab therapy, the patient's CBC began to recover.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 50 条
  • [41] Pembrolizumab-induced thrombotic thrombocytopenic purpura
    Dickey, Marcus S. R.
    Raina, Anant J.
    Gilbar, Peter J.
    Wisniowski, Brendan L.
    Collins, Joel T.
    Karki, Bhaskar
    Nguyen, Andrew D. k
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1237 - 1240
  • [42] Pembrolizumab-Induced Enterocolitis: An Emerging Phenomenon
    Thota, Vihitha
    Konduru, Sudheer
    Thota, Manaswitha
    Kagita, Navyamani
    Iqbal, Sabah
    Thirumaran, Rajesh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S759 - S759
  • [43] A case of severe Pembrolizumab-induced neutropenia
    Barbacki, Ariane
    Maliha, Peter G.
    Hudson, Marie
    Small, David
    ANTI-CANCER DRUGS, 2018, 29 (08) : 817 - 819
  • [44] Pembrolizumab-induced reactivation of bullous pemphigoid
    Kaul, Subuhi
    Wang, Allison
    Grushchak, Solomiya
    Albrecht, Joerg
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (06) : 757 - 758
  • [45] Pembrolizumab-induced subacute sensory ataxia
    Furness, A. J. S.
    Coebergh, J.
    Wood, M.
    Irvine-Sellars, M.
    Saikia, S.
    Sharma, S.
    McBride, B.
    Johnson, C.
    Teoh, M.
    Cockroft, F.
    Wing, S.
    Murray, R.
    Hewish, M.
    LUNG CANCER, 2018, 115 : S8 - S9
  • [46] Pembrolizumab-Induced Ketoacidosis: A Case Report
    Guimaraes, Francisco
    Polishchuk, Nataliya
    Martins, Claudia Almeida
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [47] Pembrolizumab-Induced Nodular Posterior Scleritis
    McNelly, Calvin L.
    Haider, Asghar A.
    Wann, Robert C.
    Crosson, Jason N.
    Mason, John O.
    JOURNAL OF VITREORETINAL DISEASES, 2023, 7 (04) : 348 - 351
  • [48] Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis
    Williams, Harriet
    Aitchison, Robin
    BMJ CASE REPORTS, 2019, 12 (12)
  • [49] Pembrolizumab-induced follicular eruption and response to isotretinoin
    O'Connor, Cathal
    Power, Derek
    Gleeson, Catherine
    Heffron, Cynthia
    IMMUNOTHERAPY, 2022, 14 (03) : 179 - 184
  • [50] Pembrolizumab-Induced Pancreatitis: Take It With a Grain of Salt
    Gajjar, Prachi C.
    Parmar, Parth
    Gajjar, Hetvi
    Upreti, Shikha
    Shah, Munir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)